LAUSR

Resveratrol and its derivative, oxyresveratrol, have various pharmacological effects. Several studies demonstrated the anticancer activity of resveratrol. However, little is known about the anticancer activity of oxyresveratrol. In this study, we compared the antiproliferative and antiangiogenic effects of oxyresveratrol and resveratrol. Three head and neck squamous cell carcinoma cell lines (HSC-3, HN-8, and HN-30) were treated with a range of concentrations of either resveratrol or oxyresveratrol. MTT assays demonstrated that resveratrol and oxyresveratrol significantly inhibited cell survival in a dose-dependent manner. Although ELISA and Real-time PCR revealed that oxyresveratrol inhibited vascular endothelial growth factor (VEGF) expression at both the mRNA and protein level, the reduction was lower than that of resveratrol. Altogether, these findings indicate that oxyresveratrol possesses anticancer properties by inhibiting cancer cell proliferation and VEGF expression. However, its efficacy is lower compared with that of resveratrol.